Helix BioPharma Corp. (HBP : TSX)
Common Stock
$0.92
CAD
+0.02 (2.22%)
Last updated: 2026-10-08
Follow HBP
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
+2.22%
1 Week
-3.16%
1 Month
-48.89%
YTD
-61.67%
Key Statistics
Market Cap
$70.27M
52W High
$3.00
52W Low
$0.85
P/E Ratio
-
50 Day MA
$1.53
200 Day MA
$1.74
Beta
-0.14
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/8/2026 | $0.94 | $0.94 | $0.92 | $0.92 | $0.92 | 3,823 |
| 10/7/2026 | $0.90 | $0.90 | $0.90 | $0.90 | $0.90 | 4,261 |
| 10/6/2026 | $0.92 | $0.92 | $0.92 | $0.92 | $0.92 | 504 |
| 10/5/2026 | $0.85 | $0.99 | $0.85 | $0.98 | $0.98 | 32,658 |
| 10/2/2026 | $0.95 | $0.98 | $0.95 | $0.98 | $0.98 | 7,134 |
| 10/1/2026 | $0.91 | $0.97 | $0.91 | $0.95 | $0.95 | 35,660 |
| 9/30/2026 | $0.96 | $1.10 | $0.91 | $0.91 | $0.91 | 42,132 |
| 9/29/2026 | $0.95 | $1.13 | $0.92 | $1.06 | $1.06 | 63,061 |
| 9/28/2026 | $1.00 | $1.14 | $0.96 | $1.14 | $1.14 | 14,755 |
| 9/25/2026 | $0.99 | $1.08 | $0.99 | $1.03 | $1.03 | 1,463 |
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 171.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+171.7% Upside
Current Price
C$0.92
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
109.6%
Annualized
90-Day Vol
76.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.87 | C$0.59 – C$1.27 |
| 60 trading days | C$0.82 | C$0.48 – C$1.39 |
| 90 trading days | C$0.77 | C$0.40 – C$1.48 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Aug 16, 2024
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About HBP
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| FTG | Firan Technology Group Corporation | $32.00 | +25.93% |
| BNG | Bengal Energy Ltd | $0.03 | +25.00% |
| PRN | Profound Medical Corp | $9.84 | +20.59% |
| RCH | Richelieu Hardware Ltd. | $38.63 | +11.39% |
| LUC | Lucara Diamond Corp | $0.15 | +11.11% |
| TVA-B | TVA Group Inc | $2.49 | +10.67% |
| THNC | Thinkific Labs Inc | $2.05 | +10.22% |
| MCB | Mccoy Global Inc | $2.65 | +9.50% |
HBP.TO news timeline
15 articles covering HBP.TO, most recent first
LatestWhat's Going On With Helix BioPharma Corp. Stock Friday?
October 2026
September 2026
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock surged yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- What's Going On With Helix BioPharma Corp. Stock Tuesday?
- Why Helix BioPharma Corp. stock fell yesterday
- What's Going On With Helix BioPharma Corp. Stock Monday?
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock is plummeting today